Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2013

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Substantive Development Milestone Payments Eligible to Receive under Astellas Collaboration Agreement

The remaining $277.0 million in substantive development milestone payments the Company is eligible to receive under the Astellas Collaboration Agreement are as follows:

Milestone Event	4th line prostate  cancer patients (1)			3rd line prostate  cancer patients (2)		2nd line prostate  cancer patients (3) (4)
First acceptance for filing of a marketing application in:
The U.S.		(5	)	$	10 million	$	15 million
The first major country in Europe		(5	)	$	5 million	$	10 million
Japan	$	5 million		$	5 million	$	10 million
First approval of a marketing application in:
The U.S.		(5	)	$	30 million	$	60 million
The first major country in Europe	$	15 million		$	15 million	$	30 million
Japan	$	15 million		$	15 million	$	30 million

⁽¹⁾  Defined as prostate cancer patients who meet each of the following three criteria: (a) prior treatment failure on either (i) one or more luteinizing hormone-releasing hormone, or LHRH, analog drugs or (ii) surgical castration; (b) prior treatment failure on one or more androgen receptor antagonist drugs; and (c) prior treatment failure on chemotherapy.

⁽²⁾  Defined as prostate cancer patients who meet each of the following three criteria: (a) prior treatment failure on either (i) one or more LHRH analog drugs or (ii) surgical castration; (b) prior treatment failure on one or more androgen receptor antagonist drugs; and (c) no prior exposure to chemotherapy for prostate cancer.

⁽³⁾  Defined as prostate cancer patients who meet each of the following two criteria: (a) prior treatment failure on either (i) one or more LHRH analog drugs or (ii) surgical castration; and (b) no prior treatment failure on one or more androgen receptor antagonist drugs.

⁽⁴⁾  An additional milestone payment of $7.0 million is payable upon the first to occur of: (a) first approval of a marketing application in the United States with a label encompassing 2nd line prostate cancer patients; (b) first approval of a marketing application in the first major country in Europe with a label encompassing 2nd line prostate cancer patients; (c) first approval of a marketing application in Japan with a label encompassing 2nd line prostate cancer patients; or (d) first patient dosed in a Phase 3 clinical trial other than the PREVAIL trial that is designed specifically to support receipt of marketing approval in 2nd line patients.

⁽⁵⁾  These milestone payments totaling $58.0 million have been previously earned and the related payments have been received.

Schedule of Collaboration Revenue

Collaboration revenue was as follows:

	Three Months Ended March 31,
	2013		2012
Collaboration revenue:
Attributable to U.S. XTANDI sales	$	37,689	$	—
Attributable to ex-U.S. XTANDI sales		—		—
Attributable to up-front and milestone payments		8,465		36,825
Total	$	46,154	$	36,825

Schedule of Collaboration Revenue Attributable to Sales

Collaboration revenue attributable to U.S. XTANDI sales was as follows:

	Three Months Ended March 31, 2013
Net U.S. sales (as reported by Astellas)	$	75,378
Shared U.S. development and commercialization costs		(57,670	)
Pre-tax U.S. profit	$	17,708
Medivation’s share of pre-tax U.S. profit	$	8,854
Reimbursement of Medivation’s share of shared U.S. costs		28,835
Collaboration revenue attributable to U.S. XTANDI sales	$	37,689

Schedule of Collaboration Revenue Attributable to Up-Front and Milestone Payments

Collaboration revenue attributable to up-front and milestone payments was as follows:

	Three Months Ended March 31,
	2013		2012
Collaboration revenue attributable to up-front and milestone payments:
From Astellas	$	8,465	$	5,937
From Pfizer		—		30,888
Total	$	8,465	$	36,825

Deferred Revenue

Deferred revenue under the Astellas Collaboration Agreement consisted of the following:

	March 31, 2013		December 31, 2012
Current	$	33,862	$	33,862
Long-term		—		8,465
Total	$	33,862	$	42,327

Development and Commercialization Cost-Sharing Payments

The following table summarizes the reductions in R&D related to cost-sharing payments:

	Three Months Ended March 31,
	2013		2012
Development cost-sharing payments from Astellas	$	7,238	$	14,115
Development cost-sharing payments from Pfizer		—		1,327
Total	$	7,238	$	15,442

The following table summarizes the (increases) reductions in SG&A related to cost-sharing payments:

	Three Months Ended March 31,
	2013			2012
Commercialization cost-sharing payments to Astellas	$	(4,785	)	$	(816	)
Commercialization cost-sharing payments from Pfizer		—			4
Total	$	(4,785	)	$	(812	)